Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a/2b Study Emapalumab: A Window of Opportunity in Pediatric Aplastic Anemia

NCT06430788 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT06430788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06430788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a/2b Study Emapalumab: A Window of Opportunity in Pediatric Aplastic Anemia
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
May 21, 2024
Completion date
May 21, 2029
Enrollment
35 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

aplastic anemia, cytopenia, hypocellular marrow